EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ID3 deficiency alters chromatin accessibility at DSB sites and enhances vulnerability to HDAC inhibition

Giuditta Della Corte, Hossam Eldesouky, Julia Puchan, Sercan Öz, Elena Everatt, Ashish Goyal, Gianluca Sigismondo, Udo Oppermann, Christoph Plass, Dieter Weichenhan, Ali Bakr iD

International Journal of Cancer · 15.06.2026 · 158 (12) · 3173-3186

DOI: 10.1002/ijc.70400 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 24.02.2026. Verfasst von Giuditta Della Corte und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Inhibitor of Differentiation Proteins, Histone Deacetylase Inhibitors, Chromatin, DNA Breaks, Double-Stranded. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The inhibitor of DNA‐binding 3 (ID3) plays a crucial role in DNA double‐strand break (DSB) repair. We previously reported that ID3 loss reduced chromatin accessibility at DNA repair gene promoters, yet its exact role in DNA repair via chromatin regulation remains elusive. Using the AID‐DIvA cell system with inducible DSBs, we show that ID3 directly regulates chromatin accessibility at DSB sites, as demonstrated by reduced chromatin accessibility and lower H3K27ac levels in ID3‐knockout (KO) cells. Loss of ID3 renders cells susceptible to histone deacetylase (HDAC) inhibition, particularly to the Class I HDAC inhibitor, leading to the accumulation of unrepaired DSBs and delayed cell cycle progression. Transcriptome and proteome analyses revealed that HDAC inhibition in ID3‐KO cells results in the downregulation of gene sets involved in the regulation of cell cycle and cell division. The synthetic lethality observed between ID3 loss and Class I HDAC inhibition underscores a novel therapeutic vulnerability in ID3‐deficient cancers, driven by compounded defects in chromatin remodeling, cell cycle, and DNA repair. Our study provides new insights into the relationship between chromatin regulation and genome stability, with implications for targeted cancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inhibitor of Differentiation ProteinsHistone Deacetylase InhibitorsChromatinDNA Breaks, Double-StrandedHumansDNA RepairCell CycleAnimalsChromatin Assembly and DisassemblyNeoplasm Proteins

Substanzen

Inhibitor of Differentiation ProteinsHistone Deacetylase InhibitorsChromatinID3 protein, humanNeoplasm Proteins

Autor:innen und Institutionen

  • Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Division of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Botnar Research Centre, Oxford Translational Myeloma Centre, University of Oxford, Oxford, UK.

ORCID-Profile: Ali Bakr

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Corte, G. D., Eldesouky, H., Puchan, J., Öz, S., Everatt, E., Goyal, A., Sigismondo, G., Oppermann, U., Plass, C., Weichenhan, D., & Bakr, A. (2026). ID3 deficiency alters chromatin accessibility at DSB sites and enhances vulnerability to HDAC inhibition. International Journal of Cancer, 158(12), 3173-3186. https://doi.org/10.1002/ijc.70400

Vancouver

Corte GD, Eldesouky H, Puchan J, Öz S, Everatt E, Goyal A, et al. ID3 deficiency alters chromatin accessibility at DSB sites and enhances vulnerability to HDAC inhibition. International Journal of Cancer. 2026;158(12):3173-3186. doi:10.1002/ijc.70400

BibTeX
@article{Corte2026,
  author = {Corte, Giuditta Della and Eldesouky, Hossam and Puchan, Julia and Öz, Sercan and Everatt, Elena and Goyal, Ashish and Sigismondo, Gianluca and Oppermann, Udo and Plass, Christoph and Weichenhan, Dieter and Bakr, Ali},
  title = {ID3 deficiency alters chromatin accessibility at DSB sites and enhances vulnerability to HDAC inhibition},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {158},
  number = {12},
  pages = {3173--3186},
  doi = {10.1002/ijc.70400}
}
Kostenlos starten →